Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26618008 | 0.92 | OPRM1 (0.47) | KMT2AHRH3SLC18A3OPRM1SIGMAR1 | |
| SCHEMBL8260731 | 0.86 | L3MBTL1 (0.50) | KMT2ASLC18A3OPRM1SIGMAR1AGTR2 | |
| SCHEMBL8260718 | 0.82 | HRH3 (0.49) | HRH3HRH4SLC18A3AGTR2GRIN2B | |
| SCHEMBL8437758 | 0.81 | SIGMAR1 (0.52) | KMT2AHRH3HRH4SLC18A3OPRM1 | |
| SCHEMBL6098562 | 0.79 | KMT2A (0.43) | KMT2AAGTR2 | |
| SCHEMBL14526649 | 0.79 | ALDH1A1 (0.45) | KMT2A | |
| SCHEMBL20281451 | 0.79 | KMT2A (0.53) | KMT2AHRH3HRH4SLC18A3OPRM1 | |
| SCHEMBL11251947 | 0.78 | HRH3 (0.67) | HRH3HRH4SLC18A3OPRM1SIGMAR1 | |
| SCHEMBL17886958 | 0.78 | KMT2A (0.49) | KMT2AHRH3HRH4SLC18A3OPRM1 | |
| SCHEMBL531089 | 0.77 | HRH3 (0.70) | HRH3HRH4SLC18A3NAAAGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256186-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-7208602-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171614-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | KMT2A 3318/4885HRH3 789/4885HRH4 1785/4885 |
| US-20050085506-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | KMT2A 2232/4885HRH3 278/4885HRH4 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.